Health

Advisory

INCREASED POTENTIAL FOR DENGUE INFECTION IN TRAVELERS RETURNING FROM INTERNATIONAL AND SELECT

DOMESTIC AREAS

The Delaware Division of Public Health is forwarding this Health Alert from the Centers for Disease Control and Prevention (CDC).

Summary: Dengue virus transmission has been increasing to epidemic levels in many parts of the tropics and subtropics.

Travelers to these areas are at risk of acquiring dengue virus and developing dengue fever (DF) or the severe form of the disease, dengue

hemorrhagic fever (DHF).The Centers for Disease Control and Prevention (CDC) strongly advises that health care providers in the United

States should: 1) consider DF and DHF when evaluating patients returning from dengue-affected areas–both domestic and abroad–who

present with an acute febrile illness within two weeks of their return, 2) submit serum specimens for appropriate laboratory testing, and

3) report all presumptive and confirmed cases of DF and DHF to their local or state health department.

Background

Dengue transmission has been increasing to epidemic levels in many parts of the tropics and subtropics where it had previously been

absent or mild. Dengue-affected areas are widely distributed throughout Africa, Asia, Pacific, the Americas and the Caribbean. This

calendar year, more than 50 countries have reported evidence of dengue transmission; including 17 countries in Asia, 17 in the Americas,

10 in Africa, seven in the Caribbean, and one in the Pacific. With an extensive dengue outbreak occurring in Puerto Rico and evidence of

continued transmission in Key West, Florida, travel to certain domestic locations may also pose a risk for the traveler. The mosquitoes

known to transmit dengue virus,Aedes aegyptiandAedes albopictus, are present throughout much of the southeastern United

States and infected returning travelers may pose a risk for initiating local transmission.

Symptoms

Dengue virus infections can manifest as a subclinical infection or DF, and may develop into potentially fatal DHF. DFis a self-limited

febrile illness thatis characterized by high fever plus two or more of the following: headache, retro-orbital pain, joint pain, muscle or

bone pain, rash, mild hemorrhagic manifestations (e.g., bleeding of nose or gums, petechiae, or easy bruising), and leukopenia. Because

the incubation period for dengue infection ranges from 3 to 14 days, the patient may not present with illness until after returning from

travel. Clinical management of DF consists of symptomatic treatment (avoid aspirin, NSAIDS and corticosteroids, as they can promote

hemorrhage) and monitoring for the development of severe disease at or around the time of defervescence. A small proportion of patients

develop DHF, which is characterized by presence of resolving fever or a recent history of fever, lasting 2–7 days, any hemorrhagic

manifestation, thrombocytopenia (platelet count≤100,000/mm³), and increased

vascular permeability, evidenced by hemoconcentration, hypoalbuminemia or hypoproteinemia, ascites, or pleural effusion. DHF can result

in circulatory instability or shock. Adequate management requires timely recognition and hospitalization, close monitoring of hemodynamic

status, and judicious administration of intravascular fluids. There is no antiviral drug or vaccine against the dengue virus. Updated

guidelines for the management of dengue can be found at http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf

Recommendations

• Health care providers seeing patients with dengue-like illness who have recently traveled to Puerto Rico, Key West, Florida orinternational dengue-affected areas (See world distribution of dengue maps at http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/dengue-fever-dengue-hemorrhagic-fever.aspx)

  should report cases to the local or state health department and send specimens for laboratory testing. DF and DHF are now nationally

  notifiable conditions in the United States. Please remember that apart from individuals traveling for tourism, individuals responding to

  international disasters (e.g., Haiti earthquake), participating in medical or religious missionary work, and visiting friends and

  relatives are often returning from dengue-affected areas and should be evaluated for dengue infection if they present with dengue-like

  illness during or after their travel.

• Reporting to local public health officials and consideration of hospitalization to initiate supportive care should not be delayedpending test results. Reporting suspected dengue cases will trigger a public health investigation and the implementation of prevention

  measures.

• Specimens from patients with acute febrile illness, who returned from dengue-affected areas within the past 14 days, should besubmitted to their local or state health department, if the health department laboratory offers dengue testing.  State health

  departments with the capacity to test for dengue include: AZ, CA, CT, FL, NY, PR, and TX.

• If the local or state health department does not perform dengue testing, submit specimens directly to CDC laboratories in San Juan,Puerto Rico (address below). CDC offers free diagnostic testing for health care providers and confirmatory dengue testing for health

  department and private laboratories. A completed CDC Dengue Case Investigation Form

  (http://www.cdc.gov/Dengue/resources/DCIF_English_ColorSept1508_FINAL_.pdf) must accompany the specimens for the appropriate testing to

  be performed.

Whenever possible, submit paired acute and convalescent specimens (2 ml of centrifuged serum.) Accuracy is increased when both acute and

convalescent specimens are available for testing. But providers should not wait and should submit acute specimens as soon as available; a

convalescent specimen can be submitted when available.

Acute specimens should be collected with 5 days of initial onset of symptoms. The appropriate analysis RT-PCR for dengue virus.

Convalescent specimens should be collected within 6 to 30 days of initial onset of symptoms and analyzed by ELISA for dengue IgM.

Centers for Disease Control & Prevention

Dengue Branch

1324 Cañada Street

San Juan, Puerto Rico 00920

Tel: (787) 706-2399; Fax (787) 706-2496

For More Information

• Instructions for the preparing and delivering specimens for dengue testing to the CDC Dengue Branch is available at: www.cdc.gov/Dengue/resources/TestpolEng_2.pdf.
• Additional information about dengue is available at: www.cdc.gov/dengue
• Call CDC’s toll-free information line, 800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, which is available 24 hours a day,every day.

************************************

You are receiving this email because you are a registered member of the Delaware Health Alert Network. If you are not a member and would

like to subscribe, please register at https://healthalertde.org

Please note: Some of the files available on this page are in Adobe PDF format which requires Adobe Acrobat Reader. A free copy of Adobe Acrobat Reader can be downloaded directly from Adobe . If you are using an assistive technology unable to read Adobe PDF, please either view the corresponding text only version (if available) or visit Adobe’s Accessibility Tools page.